Immunotherapy in the Treatment of Autoimmune Neuromuscular Diseases



A number of immunotherapies are now increasingly used to treat the autoimmune neuromuscular diseases. The specific treatments and their utilization for particular neuromuscular conditions are discussed in this chapter. This chapter also offers practical guidelines that can help clinicians use immunosuppressive or immunomodulating drugs prudently and safely. In addition, new or emerging therapies used in these diseases, including biological agents (monoclonal antibodies or recombinant proteins), are reviewed. The immunotherapeutic agents are discussed in general in the first part of the chapter, followed by a disease-specific step-by-step approach.


Immunotherapy intravenous immunoglobulin Corticosteroids Plasma Exchange Immunosuppressive agents inflammatory neuropathies neuromuscular junction disorders inflammatory myopathies 


  1. 1.
    Dalakas MC, Engel WK. Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. Ann Neurol. 1981;10(Suppl):134–45.CrossRefGoogle Scholar
  2. 2.
    Boumpas DT, Chrousos GP, Wilder RL, et al. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med. 1993;119:1198.PubMedCrossRefGoogle Scholar
  3. 3.
    Horst HJ, Flad HD. Corticosteroid-interleukin 2 interactions: inhibition of binding of interleukin 2 to interleukin 2 receptors. Clin Exp Immunol. 1987;68:156.PubMedGoogle Scholar
  4. 4.
    Dalakas MC. Basic aspects of neuroimmunology as they relate to immunotherapeutic targets: present and future prospects. Ann Neurol. 1995;37(Suppl):2–13.CrossRefGoogle Scholar
  5. 5.
    Dalakas MC. Pharmacologic concerns of corticosteroids in the treatment of patients with immune-related neuromuscular diseases. Neurol Clin. 1990;8:93–118.PubMedGoogle Scholar
  6. 6.
    Frauman AG. An overview of the adverse reactions to adrenal corticosteroids. Adverse Drug React Toxicol Rev. 1996;15:203–6.PubMedGoogle Scholar
  7. 7.
    Dalakas MC. Inflammatory myopathies: management of steroid resistance. Curr Opin Neurol. 2011;24:457–62.PubMedCrossRefGoogle Scholar
  8. 8.
    Lopate G, Pestronk A, Al-Lozi M. Treatment of chronic inflammatory demyelinating polyneuropathy with high dose intermittent intravenous methylprednisolone. Arch Neurol. 2005;2005:249–54.CrossRefGoogle Scholar
  9. 9.
    Lacomis D, Zivković SA. Approach to vasculitic neuropathies. J Clin Neuromuscul Dis. 2007;9(1):265–76.PubMedCrossRefGoogle Scholar
  10. 10.
    Nobile-Orazio E. Update on neuropathies associated with monoclonal gammopathy of undetermined significance (2008–2010). J Peripher Nerv Syst. 2010;5(4):302–6.CrossRefGoogle Scholar
  11. 11.
    Lehmann HC, Hartung HP, Hetzel GR, Stuve O, Kieseier BC. Plasma exchange in neuroimmunological disorders. Arch Neurol. 2006;63:1066–71.PubMedCrossRefGoogle Scholar
  12. 12.
    Seybold ME. Plasmapheresis in myasthenia gravis. Ann N Y Acad Sci. 1987;505:584–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Ame AN. Assessment of plasmapheresis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 1996;47:840–3.CrossRefGoogle Scholar
  14. 14.
    Dalakas MC. Intravenous immunoglobulin therapy for neurological diseases. Ann Intern Med. 1997;126:721–30.PubMedCrossRefGoogle Scholar
  15. 15.
    Dalakas MC. The use of intravenous immunoglobulin for neurologic diseases. Neurology. 1998;51 Suppl 5Suppl. 5:S1.CrossRefGoogle Scholar
  16. 16.
    Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther. 2004;102:177–93.PubMedCrossRefGoogle Scholar
  17. 17.
    Dalakas MC. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology. 1998;51(Suppl):S2–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Lehmann HC, Hartung HP. Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies. J Neuroimmunol. 2011;231:61–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Katz U, Shoenfeld Y, Zandman-Goddard G. Update on intravenous immunoglobulins (IVIg) mechanisms of action and off-label use in autoimmune diseases. Curr Pharm Des. 2011;17:166–75.CrossRefGoogle Scholar
  20. 20.
    Rezaei N, Abolhassani H, Aghamohammadi A, Ochs HD. Indications and safety of intravenous and subcutaneous ­immunoglobulin therapy. Expert Rev Clin Immunol. 2011;7:301–16.PubMedCrossRefGoogle Scholar
  21. 21.
    Silbert PL, Knezevic WV, Bridge DT. Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology. 1992;42:257–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Steg RE, Lefkowitz DM. Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis. Neurology. 1994;44:1180–1.PubMedCrossRefGoogle Scholar
  23. 23.
    Woodruff RK, Griff AP, Firkin FL, Smith IL. Fatal thrombic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet. 1986;2:217–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Constantinescu CS, Chang AP, McClusky LF. Recurrent migraine and intravenous immune globulin therapy. N Engl J Med. 1993;329:583–4.PubMedCrossRefGoogle Scholar
  25. 25.
    Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994;121:259–62.PubMedCrossRefGoogle Scholar
  26. 26.
    Dalakas MC. Aseptic meningitis and intravenous immunoglobulin. Ann Intern Med. 1995;122:316–7.CrossRefGoogle Scholar
  27. 27.
    Asham N. Intravenous immunoglobulin induced-nephropathy: a complication of IVIg therapy. J Nephrol. 1998;11:157–61.Google Scholar
  28. 28.
    Asham N, Palmer BF, Wheeler D, et al. Intravenous immunoglobulin-induced osmotic nephrosis. Arch Intern Med. 1994;154:1985–7.CrossRefGoogle Scholar
  29. 29.
    Dalakas MC. Meningitis and skin reactions after intravenous immunoglobulin therapy. Ann Intern Med. 1997;127:1130.CrossRefGoogle Scholar
  30. 30.
    Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. N Engl J Med. 1986;314:560–4.PubMedCrossRefGoogle Scholar
  31. 31.
    Rachid R, Castells M, Cunningham-Rundles C, Bonilla FA. Association of anti-IgA antibodies with adverse reactions to gamma globulin infusion. J Allergy Clin Immunol. 2011;128:228–30.PubMedCrossRefGoogle Scholar
  32. 32.
    Hughes RAC, Swan AV, Raphael JC. Immunotherapy for Guillain-Barre syndrome: a systematic review. Brain. 2007;130:2245–57.PubMedCrossRefGoogle Scholar
  33. 33.
    Plasma Exchange/Sandoglobulin Guillain-Barré syndrome Trial Group. Randomized trial of plasma exchange, intravenous immunoglobulin, and plasma exchange followed by intravenous immunoglobulin in Guillain-Barré syndrome. Lancet. 1997;349:225–30.CrossRefGoogle Scholar
  34. 34.
    van der Meche FG, Schmitz PI, Dutch Guillain Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med. 1992;326:1123–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Vermeulen M et al. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1993;56:36–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Mendell JR et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 2001;56:445–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Dyck PJ et al. A plasma exchange versus immune globulin infusion trial in chronic inflamatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994;36:838–45.PubMedCrossRefGoogle Scholar
  38. 38.
    van Doorn PA, Brand A, Strengers PF, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology. 1990;40:209–12.PubMedCrossRefGoogle Scholar
  39. 39.
    Hahn AF, Bolton CF, Xochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating ­polyneuropathy (CIDP): a double-blind, placebo-controlled, ­cross-over study. Brain. 1995;119:1067–78.CrossRefGoogle Scholar
  40. 40.
    Hughes RAC et al. Intravenous immune globulin (10 % caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7:136–44.PubMedCrossRefGoogle Scholar
  41. 41.
    Azulay JP, Blin O, Pouget J, Boucrout J, Bille-Turc F, Carles G, et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology. 1994;44:429–32.PubMedCrossRefGoogle Scholar
  42. 42.
    Van den Berg LH et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1995;59:248–52.PubMedCrossRefGoogle Scholar
  43. 43.
    Federico P, Zochodne DW, Hahn AF, Brown WF, Feasby TE. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology. 2000;55:1256–62.PubMedCrossRefGoogle Scholar
  44. 44.
    Leger JM et al. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain. 2001;124:145–53.PubMedCrossRefGoogle Scholar
  45. 45.
    Van den Berg-Vos RM, Franssen H, Wokke JH, Van den Berg LH. Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain. 2002;125:1875–86.PubMedCrossRefGoogle Scholar
  46. 46.
    Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993–2000.PubMedCrossRefGoogle Scholar
  47. 47.
    Bain PG, Motomura M, Newsom-Davis J, Misbah SA, Chapel HM, Lee ML, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology. 1996;47:678–83.PubMedCrossRefGoogle Scholar
  48. 48.
    Gajdos PH, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol. 1997;41:789–96.PubMedCrossRefGoogle Scholar
  49. 49.
    Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. 2007;68:837–41.PubMedCrossRefGoogle Scholar
  50. 50.
    Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76(23):2017–23.PubMedCrossRefGoogle Scholar
  51. 51.
    Dalakas MC, Quarles RH, Farrer RG, et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol. 1996;40:792–5.PubMedCrossRefGoogle Scholar
  52. 52.
    Comi G, Roveri L, Swan A, et al. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol. 2002;249:1370–7.PubMedCrossRefGoogle Scholar
  53. 53.
    Dalakas MC, Sonies B, Dambrosia J, Sekul EA, Cupler EJ, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology. 1997;48:712–6.PubMedCrossRefGoogle Scholar
  54. 54.
    Cherin P, Herson S, Wechsler B, Piette JC, Bletry O, Coutellier A, et al. Efficacy of intravenous immunoglobulin therapy in chronic refractory polymyositis and dermatomyositis. An open study with 20 adult patients. Am J Med. 1991;91:162–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Cherin P, Pelletier S, Teixeira A, Laforet P, Genereau T, Simon A, et al. Results and long-term follow-up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum. 2002;46:467–74.PubMedCrossRefGoogle Scholar
  56. 56.
    Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am. 2008;28:779–802.PubMedCrossRefGoogle Scholar
  57. 57.
    Köller H, Schroeter M, Feischen H, et al. Subcutaneous self-­infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies. J Neurol. 2006;253:1505–6.PubMedCrossRefGoogle Scholar
  58. 58.
    Lee DH, Linker RA, Paulus W, et al. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2008;37:406–9.PubMedCrossRefGoogle Scholar
  59. 59.
    Harbo T, Andersen H, Hess A, et al. Subcutaneous versus intravenous immunoglobulin treatment for MMN patients: a randomized, single-blinded, cross-over study. Eur J Neurol. 2009;16:631–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Kissel JT, Levy RJ, Mendell JR, et al. Azathioprine toxicity in ­neuromuscular disease. Neurology. 1986;36:35–9.PubMedCrossRefGoogle Scholar
  61. 61.
    Slanar O, Chalupná P, Novotný A, Bortlík M, Krska Z, Lukás M. Fatal myelotoxicity after azathioprine treatment. Nucleosides Nucleotides Nucleic Acids. 2008;27:661–5.PubMedCrossRefGoogle Scholar
  62. 62.
    Confavreax C, Saddier P, Grimaud J, et al. Risk of cancer from azathioprine therapy in multiple sclerosis: a case–control study. Neurology. 1996;46:1607–12.CrossRefGoogle Scholar
  63. 63.
    Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology. 1998;50:1778–83.PubMedCrossRefGoogle Scholar
  64. 64.
    Mahdi-Rodgers M, Swan AV, van Doorn PA, Hughes RAC. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for CIDP. Cochrane Database Syst Rev. 2010;11. Art. No.: CD003280. doi: 10.1002/14651858.CD003280.pub3.
  65. 65.
    Dyck PJ, O’Brien P, Swanson C, Low P, Daube J. Combined azathioprine and prednisone in chronic inflammatory demyelinating polyneuropathy. Neurology. 1985;35:1173–6.PubMedCrossRefGoogle Scholar
  66. 66.
    Bunch TW, Worthington JW, Combs JJ, et al. Azathioprine with prednisone for polymyositis: a controlled, clinical trial. Ann Intern Med. 1980;92:365–9.PubMedCrossRefGoogle Scholar
  67. 67.
    Bunch TW. Prednisone and azathioprine for polymyositis: long-term follow-up. Arthritis Rheum. 1981;24:45–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Villarroel MC, Hidalgo M, Jimeno A. Mycophenolate mofetil: an update. Drugs Today. 2009;45(7):521–32.PubMedGoogle Scholar
  69. 69.
    Neff RT, Hurst FP, Falta EM, Bohen EM, Lentine KL, Dharnidharka VR, et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Trans­plantation. 2008;86(10):1474–8.PubMedCrossRefGoogle Scholar
  70. 70.
    Hehir MK, Burns TM, Alpers J, Conaway MR, Sawa M, Sanders DB. Mycophenolate mofetil in AChR-positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve. 2010;41:593–8.PubMedCrossRefGoogle Scholar
  71. 71.
    Meriggioli MN, Ciafaloni E, Al-Hayk KA, Rowin J, Tucker-Lipscomb B, Massey JM, et al. Mycophenolate mofetil in the ­treatment of myasthenia gravis: an analysis of efficacy, safety and tolerability. Neurology. 2003;61:1438–40.PubMedCrossRefGoogle Scholar
  72. 72.
    The Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology. 2008;71:394–9.CrossRefGoogle Scholar
  73. 73.
    Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqui ZA, DeBaets MH, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology. 2008;71:400–6.PubMedCrossRefGoogle Scholar
  74. 74.
    Vermersch P, Stojkovic T, de Seze J. Mycophenolate mofetil and neurological diseases. Lupus. 2005;14 Suppl 1Suppl 1:s42–5.PubMedCrossRefGoogle Scholar
  75. 75.
    Cronstein B. How does methotrexate suppress inflammation? Clin Exp Rheumatol. 2010;28(5 Suppl 61):S21–3.PubMedGoogle Scholar
  76. 76.
    Distad BJ, Amato AA, Weiss MD. Inflammatory myopathies. Curr Treat Options Neurol. 2011;13(2):119–30.PubMedCrossRefGoogle Scholar
  77. 77.
    Eftimov F, Van Schaik IN. Immunotherapy of multifocal motor neuropathy. Expert Opin Biol Ther. 2011;11:329–42.PubMedCrossRefGoogle Scholar
  78. 78.
    Good JL, Chehrenama M, Mayer RF, Koski CL. Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology. 1998;51:1735–8.PubMedCrossRefGoogle Scholar
  79. 79.
    Collins MP, Dyck PJ, Gronseth GS, Guillevin L, Hadden RD, Heuss D, et al. Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. J Peripher Nerv Syst. 2010;15(3):176–84.PubMedCrossRefGoogle Scholar
  80. 80.
    Dalakas MC. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol. 2010;6:129–37.PubMedCrossRefGoogle Scholar
  81. 81.
    Ciafaloni E, Nikhar NK, Massey JM, Sanders DB. Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology. 2000;55:448–50.PubMedCrossRefGoogle Scholar
  82. 82.
    Tindall RS, Phillips JT, Rollins JA, Wells L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci. 1993;681:539–51.PubMedCrossRefGoogle Scholar
  83. 83.
    Cocito D, Grimaldi S, Paolasso I, Falcone Y, Antonini G, Benedetti L, et al. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis. Eur J Neurol. 2011;12:1417–21.CrossRefGoogle Scholar
  84. 84.
    Ponseti JM, Gamez J, Lopez-Cano M, Vilalloga R, Armengol M. Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann N Y Acad Sci. 2008;1132:254–63.PubMedCrossRefGoogle Scholar
  85. 85.
    Konishi T, Yoshiyama Y, Takamori M, Saida T. Long-term treatment of generalized myasthenia gravis with FK506 (tacrolimus). J Neurol Neurosurg Psychiatry. 2005;76:448–50.PubMedCrossRefGoogle Scholar
  86. 86.
    Nagane Y, Utsugisawa K, Obara D, Knodoh R, Terayama Y. Efficacy of low-dose FK-506 in the treatment of myasthenia gravis-a randomized pilot study. Eur Neurol. 2005;53:146–50.PubMedCrossRefGoogle Scholar
  87. 87.
    Takamori M, Motomura M, Kawaguchi N, Nemoto Y, Hattori T, Yoshikawa H, et al. Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis. Neurology. 2004;62:1894–6.PubMedCrossRefGoogle Scholar
  88. 88.
    De Sousa EA, Brannagan 3rd TH. Diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy. Curr Treat Options Neurol. 2006;8(2):91–103.PubMedCrossRefGoogle Scholar
  89. 89.
    Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010;47(2):115–23.PubMedCrossRefGoogle Scholar
  90. 90.
    Dalakas MC. B-cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol. 2008;4:557–67.PubMedCrossRefGoogle Scholar
  91. 91.
    Arkfeld DG. The potential utility of B-cell-directed biologic therapy in autoimmune diseases. Rheumatol Int. 2008;28:205–15.PubMedCrossRefGoogle Scholar
  92. 92.
    Zhou X, Hu W, Qin X. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist. 2008;13(9):954–66.PubMedCrossRefGoogle Scholar
  93. 93.
    Kimby E. Tolerability and safety of Rituximab (MabThera). Cancer Treat Rev. 2005;31:456–73.PubMedCrossRefGoogle Scholar
  94. 94.
    Bosch X, Saiz A, Ramos-Casals M. BIOGEAS Study Group. Monoclonal antibody therapy-associated neurological disorders. Nat Rev Neurol. 2011;7:165–72.PubMedCrossRefGoogle Scholar
  95. 95.
    Tavazzi E, Ferrante P, Khalili K. Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies. Clin Microbiol Infect. 2011;17(12):1776–80.PubMedCrossRefGoogle Scholar
  96. 96.
    Dalakas MC, Racocevic G, Salajegheh M, Dambrosia JM, Hahn AF, Raju R, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol. 2009;65:286–93.PubMedCrossRefGoogle Scholar
  97. 97.
    Briani C, Zara G, Zambello R, Trentin L, Rana M, Zaja F. Rituximab-responsive CIDP. Eur J Neurol. 2004;11:788–91.PubMedCrossRefGoogle Scholar
  98. 98.
    Zabardast N, Patwa HS, Novella SP, Goldstein JM. Rituximab in the management of refractory myasthenia gravis. Muscle Nerve. 2010;41:375–8.CrossRefGoogle Scholar
  99. 99.
    Dalakas MC, Rakocevic G, Schmidt J, Salajegheh M, McElroy B, Harris-Love MO, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain. 2009;132(Pt 6):1536–44.PubMedCrossRefGoogle Scholar
  100. 100.
    Costelloe L, Jones J, Coles A. Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. Expert Rev Neurother. 2012;12(3):335–41.PubMedCrossRefGoogle Scholar
  101. 101.
    Rowin J, Meriggioli MN, Tüzün E, Leurgans S, Christadoss P. Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology. 2004;63:2390–2.PubMedCrossRefGoogle Scholar
  102. 102.
    Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol. 2011;70(3):427–36.CrossRefGoogle Scholar
  103. 103.
    Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55:7–15.PubMedCrossRefGoogle Scholar
  104. 104.
    Farge D, Labopin M, Tyndall A, Fassas A, Mancardi GL, Van Laar J, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years’ experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica. 2010;95(2):284–92.PubMedCrossRefGoogle Scholar
  105. 105.
    Strober J, Cowan MJ, Horn BN. Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis. Arch Neurol. 2009;66(5):659–61.PubMedCrossRefGoogle Scholar
  106. 106.
    Mahdi-Rogers M, Kazmi M, Ferner R, Hughes RA, Renaud S, Steck AJ, et al. Autologous peripheral blood stem cell transplantation for chronic acquired demyelinating neuropathy. J Peripher Nerv Syst. 2009;14(2):118–24.PubMedCrossRefGoogle Scholar
  107. 107.
    Van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barre syndrome. Lancet. 2008;7:939–50.CrossRefGoogle Scholar
  108. 108.
    Guillain-Barré Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology. 1985;35:1096–104.CrossRefGoogle Scholar
  109. 109.
    French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol. 1987;22:753–61.CrossRefGoogle Scholar
  110. 110.
    The French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Plasma exchange in Guillain Barre syndrome: one-year follow-up. Ann Neurol. 1992;32:94–7.CrossRefGoogle Scholar
  111. 111.
    Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994;36:838–45.PubMedCrossRefGoogle Scholar
  112. 112.
    Susuki K, Yuki N. Effect of methylprednisolone in patients with Guillain Barre syndrome. Lancet. 2004;363:1236–7.PubMedCrossRefGoogle Scholar
  113. 113.
    Hughes RA, Swan AV, van Koningsveld R, van Doorn PA. Corticosteroids for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2006;2:CD001446.Google Scholar
  114. 114.
    van Koningsveld R, Schmitz PI, Ang CW, et al. Infections and course of disease in mild forms of Guillain-Barre syndrome. Neurology. 2002;58:610–4.PubMedCrossRefGoogle Scholar
  115. 115.
    Visser LH, van der Meche FG, Meulstee J, van Doorn PA. Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome. Dutch Guillain-Barré study group. J Neurol Neurosurg Psychiatry. 1998;64:242–4.PubMedCrossRefGoogle Scholar
  116. 116.
    Romano JG, Rotta FT, Potter P, Rosenfeld V, Santibanez R, Rocha B, et al. Relapses in the Guillain-Barré syndrome after treatment with intravenous immune globulin or plasma exchange. Muscle Nerve. 1998;21:1327–30.PubMedCrossRefGoogle Scholar
  117. 117.
    Nagappon R, Barker J. Second response to immunoglobulin in recurrent Guillain-Barré syndrome. N Z Med J. 1998;13:433–4.Google Scholar
  118. 118.
    Dalakas MC. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol. 2011;7:507–17.PubMedCrossRefGoogle Scholar
  119. 119.
    Dyck PJ et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol. 1982;11:136–41.PubMedCrossRefGoogle Scholar
  120. 120.
    van Schaik IN, Eftimov F, van Doorn PA, Brusse E, van den Berg LH, van der Pol WL, et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol. 2010;9(3):245–53.PubMedCrossRefGoogle Scholar
  121. 121.
    Eftimov F, Vermeulen M, van Doorn PA, Brusse E, van Schaik IN; On behalf of the PREDICT study group. Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology. 2012;78(14):1079–84.Google Scholar
  122. 122.
    Dyck PJ et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med. 1986;314:461–5.PubMedCrossRefGoogle Scholar
  123. 123.
    Hahn AF et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double blind, sham-controlled, cross-over study. Brain. 1996;119:1055–66.PubMedCrossRefGoogle Scholar
  124. 124.
    RMC Trial Group. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol. 2009;8:158–64.CrossRefGoogle Scholar
  125. 125.
    Benedetti L, Briani C, Franciotta D, Fazio R, Paolasso I, Comi C, et al. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry. 2011;82:306–8.PubMedCrossRefGoogle Scholar
  126. 126.
    Vlam L, van der Pol WL, Cats EA, Straver DC, Piepers S, Franssen H, et al. Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol. 2011;8(1):48–58.PubMedCrossRefGoogle Scholar
  127. 127.
    Cats EA et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology. 2010;75:818–25.PubMedCrossRefGoogle Scholar
  128. 128.
    Slee M, Selvan A, Donaghy M. Multifocal motor neuropathy: the diagnostic spectrum and response to treatment. Neurology. 2007;69:1680–7.PubMedCrossRefGoogle Scholar
  129. 129.
    Van Asseldonk JT, Van den Berg LH, Van den Berg-Vos RM, Wieneke GH, Wokke JH, Franssen H. Demyelination and axonal loss in multifocal motor neuropathy: distribution and relation to weakness. Brain. 2003;126:186–98.PubMedCrossRefGoogle Scholar
  130. 130.
    Van den Berg LH, Lokhorst H, Wokke JH. Pulsed high-dose dexamethasone is not effective in patients with multifocal motor neuropathy. Neurology. 1997;48:1135.PubMedCrossRefGoogle Scholar
  131. 131.
    Carpo M, Cappellari A, Mora G, Pedotti R, Barbieri S, Scarlato G, et al. Deterioration of multifocal motor neuropathy after plasma exchange. Neurology. 1998;50:1480–2.PubMedCrossRefGoogle Scholar
  132. 132.
    Piepers S, Van den Berg-Vos R, Van der Pol WL, Franssen H, Wokke J, Van den Berg L. Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial. Brain. 2007;130:2004–10.PubMedCrossRefGoogle Scholar
  133. 133.
    Fitzpatrick AM, Mann CA, Barry S, Brennan K, Overell JR, Willison HJ. An open label clinical trial of complement inhibition in multifocal motor neuropathy. J Peripher Nerv Syst. 2011;16:84–91.PubMedCrossRefGoogle Scholar
  134. 134.
    van Schaik IN, van den Berg LH, de Haan R, Vermeulen M. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev. 2005;(2):CD004429.Google Scholar
  135. 135.
    Kyle RA, Dyck PJ. Neuropathy associated with the monoclonal gammopathies. In: Dyck PJ, Thomas PK, editors. Peripheral ­neuropathy. 4th ed. Philadelphia: Elsevier Saunders; 2005. p. 2255–76.CrossRefGoogle Scholar
  136. 136.
    Nobile-Orazio E, Meucci N, Baldini L, et al. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain. 2000;123:710–7.PubMedCrossRefGoogle Scholar
  137. 137.
    Dalakas MC, Rakocevic G, Salajegheh M. Placebo-controlled trial of rituximab in IgM anti-myelin associated glycoprotein antibody demyelinating neuropathy. Ann Neurol. 2009;65:286–93.PubMedCrossRefGoogle Scholar
  138. 138.
    Guillevin L, Pagnoux C. Indications of plasma exchanges for systemic vasculitides. Ther Apher Dial. 2003;7:155–60.PubMedCrossRefGoogle Scholar
  139. 139.
    Collins MP, Periquet-Collins I. Nonsystemic vasculitic neuropathy: update on diagnosis, classification, pathogenesis, and treatment. Front Neurol Neurosci. 2009;26:26–66.PubMedCrossRefGoogle Scholar
  140. 140.
    Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475–90.PubMedCrossRefGoogle Scholar
  141. 141.
    Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol. 1984;15:291–8.PubMedCrossRefGoogle Scholar
  142. 142.
    Sgirlanzoni A, Peluchetti D, Mantegazza R, Fiacchino F, Cornelio F. Myasthenia gravis: prolonged treatment with steroids. Neurology. 1984;34:170–4.CrossRefGoogle Scholar
  143. 143.
    Cosi V, Citterio A, Lombardi M, Piccolo G, Romani A, Erbetta A. Effectiveness of steroid treatment in myasthenia gravis: a retrospective study. Acta Neurol Scand. 1991;84:33–9.PubMedCrossRefGoogle Scholar
  144. 144.
    Evoli A, Batocchi AP, Palmisani MT, Lo Monaco M, Tonali P. Long-term results of corticosteroid therapy in patients with myasthenia gravis. Eur Neurol. 1992;32:37–43.PubMedCrossRefGoogle Scholar
  145. 145.
    Kuks JBM. Azathioprine in myasthenia gravis: observations in 41 patients and a review of the literature. Neuromuscul Disord. 1991;1:423–31.PubMedCrossRefGoogle Scholar
  146. 146.
    De Feo LG, Schottlender J, Martelli NA, Molfino NA. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve. 2002;26:31–6.PubMedCrossRefGoogle Scholar
  147. 147.
    Drachman DB, Jones RJ, Brodsky RA. Treatment of refractory myasthenia: “rebooting” with high-dose cyclophosphamide. Ann Neurol. 2003;53:29–34.PubMedCrossRefGoogle Scholar
  148. 148.
    Illa I, Diaz-Manera J, Rojas-Garcia R, Pradas J, Rey A, Blesa R, et al. Rituximab in refractory myasthenia gravis: a follow-up study of patients with anti-MuSK or anti-MuSK antibodies. Neurology. 2008;70 Suppl 1Suppl 1:A301.Google Scholar
  149. 149.
    Tandan R, Potter C, Bradshaw DY. Pilot trial of rituximab in myasthenia gravis. Neurology. 2008;70 Suppl 1Suppl 1:A301.Google Scholar
  150. 150.
    Sanders DB, Massey JM, Sanders LL, et al. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology. 2000;54:603–7.PubMedCrossRefGoogle Scholar
  151. 151.
    Maddison P, Lang B, Mills K, et al. Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer. J Neurol Neurosurg Psychiatry. 2001;70:212–7.PubMedCrossRefGoogle Scholar
  152. 152.
    McEvoy KM, Windebank AJ, Daube JR, et al. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med. 1989;321:1567–71.PubMedCrossRefGoogle Scholar
  153. 153.
    Maddison P, McConville J, Farrugia ME, et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 2011;82(6):671–3.PubMedCrossRefGoogle Scholar
  154. 154.
    Tim RW, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrome. Electrodiagnostic findings and response to treatment. Neurology. 2000;54:2176–8.PubMedCrossRefGoogle Scholar
  155. 155.
    Dalakas MC. Immunotherapy of inflammatory myopathies: practical approach and future prospects. Curr Treat Options Neurol. 2011;13:311–23.PubMedCrossRefGoogle Scholar
  156. 156.
    Joffe MM et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med. 1993;94(4):379–87.PubMedCrossRefGoogle Scholar
  157. 157.
    Levine TD. Rituximab in the treatment of dermatomyositis: an open label pilot study. Arthritis Rheum. 2005;52:601–17.PubMedCrossRefGoogle Scholar
  158. 158.
    Mahler EA et al. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology (Oxford). 2011;50:2206–13.CrossRefGoogle Scholar
  159. 159.
    Soueidan SA, Dalakas MC. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology. 1993;43:876–9.PubMedCrossRefGoogle Scholar
  160. 160.
    Mammen A. Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol. 2011;7:343–54.PubMedCrossRefGoogle Scholar
  161. 161.
    Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum. 2004;50:209–15.PubMedCrossRefGoogle Scholar
  162. 162.
    Grable-Esposito P, Katzberg HD, Greenberg SA, et al. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve. 2010;41(2):185–90.PubMedGoogle Scholar
  163. 163.
    Mammen AL et al. Autoantibodies against 3-hydroxy-3-­methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63:713–21.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of NeurologyMichigan State University/Sparrow Health SystemsHoltUSA
  2. 2.Novartis Institute for Biomedical ResearchCambridgeUSA

Personalised recommendations